CVS Agrees to $315 Million Opioid Prescription Fraud Settlement

CVS Pharmacy Inc. and its related corporate entities have agreed to pay $315 million to resolve allegations that they filled prescriptions for opioids and other controlled substances in violation of the Controlled Substances Act and False Claims Act, the Justice Department said today.

The government alleged that CVS knowingly filled prescriptions for controlled substances that lacked a legitimate medical purpose, including dangerous and excessive quantities of opioids, prescriptions filled too early, and “trinity” prescriptions—a dangerous combination of an opioid, benzodiazepine, and muscle relaxant.

“We strongly disagree with the claims made in this case, and our settlement with the DOJ admits no wrongdoing,” CVS spokesperson Amy Thibault said. “We’re pleased to move forward and put this litigation behind us.”

The settlement “requires CVS to implement additional safeguards to ensure that prescriptions for opioids and other controlled substances are dispensed only when medically appropriate,” said Assistant Attorney General Brett A. Shumate of the Justice Department’s Civil Division.

CVS also allegedly filled prescriptions from “pill mill” prescribers who issued large numbers of controlled substance prescriptions without any medical purpose, despite clear red flags indicating the prescriptions were invalid. The complaint further alleged that CVS’s violations stemmed from corporate-imposed performance metrics, incentive compensation, and staffing policies that prioritized corporate profits over patient safety, including failing to employ enough pharmacists and preventing pharmacists from warning one another problematic prescribers.

In addition to the monetary payment, CVS has entered into a memorandum of agreement with the DEA requiring the company to establish a hotline for employees and the public to report suspected illegal dispensing, proactively monitor pharmacies’ dispensing patterns to identify potential illegality, and establish a process to detect illegal prescribing, the DOJ said.

The settlement resolves an FCA suit former CVS employee Hillary Estright filed in the US District Court for the District of Rhode Island. Her recovery under the settlement is undetermined, DOJ says. Counsel for the whistleblower didn’t immediately respond to a request for .

The settlement resolved allegations only, the announcement said.

This story was produced with the assistance of Bloomberg Law AI.

The case is United States ex rel. Estright v. CVS Health Corp. , D.R.I., No. 22-cv-22, settlement 10/13/26.

( Updates story to include statement from CVS in third paragraph. )

See Breaking News in Context

Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.

Log in to keep reading or access research tools and resources.